Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.08 EUR
Change Today -0.002 / -2.44%
Volume 0.0
LCLA On Other Exchanges
As of 9:46 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma tbk pt (LCLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/15 - €0.14
52 Week Low
09/28/15 - €0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KALBE FARMA TBK PT (LCLA)

Related News

No related news articles were found.

kalbe farma tbk pt (LCLA) Related Businessweek News

No Related Businessweek News Found

kalbe farma tbk pt (LCLA) Details

PT. Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs, energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company operates a retail health service, Mitrasana Clinics, an integrated clinic network consisting of physician’s general practice, pharmacies, laboratory, and health mart, which also offers hemodialysis services; contract services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; produces reagents; operates as an agent for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; markets and distributes ophthalmic products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. PT. Kalbe Farma Tbk. was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,626 Employees
Last Reported Date: 10/30/15
Founded in 1966

kalbe farma tbk pt (LCLA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma tbk pt (LCLA) Key Developments

Kalbe Farma (Indonesia) Provides Earnings Guidance for the Full Year 2015

Kalbe Farma (Indonesia) provided earnings guidance for the full year 2015. The company expected its full-year 2015 sales to grow 2%-3% year on year and its net profit to fall by 3%-4% year on year, amid slowing macroeconomic conditions.

Kalbe Reports Earnings Results for the Third Quarter of 2015

Kalbe reported earnings results for the third quarter of 2015. The company booked net sales of IDR 13,128 billion in the third quarter of 2015, or growing by 2.9% compared to the same period in 2014 of IDR 12,758 billion. This was mostly due to weaker purchasing power, the impact of a prescription pharmaceuticals product recall and discontinued distributorship agreement with a third party principal since end of 2014. Operating income reached IDR 1,976 billion, or equivalent to a ratio of 15.1% of net sales. Operating income decreased by 1.0% compared to the same period last year, due to a slowdown in sales growth. The company will seek to control its operating expenses gradually by improving its marketing and sales effectiveness and monitoring the other operating expenses. Net profit was relatively unchanged at IDR 1,499 billion, or just growing by 0.8% compared to IDR 1,487 billion in the same period last year. This was mostly attributable to improvement in financing expense, interest income and foreign exchange gain.

PT. Kalbe Farma Tbk. to Report Nine Months, 2015 Results on Oct 30, 2015

PT. Kalbe Farma Tbk. announced that they will report nine months, 2015 results on Oct 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCLA:GR €0.08 EUR -0.002

LCLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LCLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation LCLA Industry Range
Price/Earnings 32.6x
Price/Sales 3.8x
Price/Book 6.8x
Price/Cash Flow 32.6x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KALBE FARMA TBK PT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at